Hepatic Resection for Colorectal Liver Metastases following Panitumumab(Vectibix) with Chemotherapy Cohort study
- Conditions
- nresectable colorectalcancer with hepatic metastases
- Registration Number
- JPRN-UMIN000017397
- Lead Sponsor
- Gastroenterological Surgery1, Hokkaido University Graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1.The cases with serious drug hyper reaction against panitumumab, fluorouracil folinic acid, oxaliplatin, irinotecan 2.The cases with serious hypersensitivity having functional disorder or sensory disturbance 3. The cases with bone marrow suppression or its history, systemic infection, interstitial pneumonia, diarrhea, ileus, a lot of ascites or hydrothorax, icterus 4.The cases with interstitial pneumonia or its history 5.The cases with serious complications -Poor control diabetes mellitus -Heart failure beyond NYHA3 -Renal failure -Liver failure 6.The cases with mutative or unjudged type about KRAS status 7.The cases without a history of chemotherapy 8.Pregnant or lactating women 9.The cases judged to be unsuitable for registration
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete hepatic resection rate
- Secondary Outcome Measures
Name Time Method Hepatic resection rate, response rate, complications after hepatic resection, adverse event